Abbott Laboratories (ABT) Stock AnalysisABTStock AnalysisAbbott Laboratories

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Abbott Laboratories is a good buy right now due to its recent CE Mark approval for the Amulet 360 device, which is expected to enhance its market presence and revenue potential. The current price of $112.47 is below the average analyst price target of $125, indicating a potential upside of 11.1%. Additionally, the forward P/E ratio of 20.66 suggests the stock is reasonably valued for future growth, especially with a gross margin of 52.49% in the latest quarter, reflecting strong profitability. However, a risk to consider is the recent insider selling trend, which has increased by 606.25% over the last month, indicating potential concerns among insiders about the stock's future performance.

20 analysts cover ABT: 13 rate it Buy, 7 Hold and 0 Sell. The average price target is 148.11.